Markets · News reference
Gretchen Whitmer slams Trump over Canada tariffs, says move will spike fuel and grocery prices, lead to potential job loss in auto industry.
Reference details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
No ticker was attached by the source feed.
Keep reading
Affirm Holdings (NASDAQ:AFRM) FY2027 Revenue expected to be more than $5.440B vs $5.287B Est. GMV Expected at More Than $64 Billion; Revenue/GMV Ratio Seen at 8.5%.
Read original at benzingaBitcoin rally driven by spot demand and spreading to altcoins. Bitfinex sees $80,000 as key resistance. Nineteen altcoins gain over 12%.
Read original at benzingaThe global blood-based biomarkers market is projected to grow from USD 8.5 billion in 2025 to USD 18.5 billion by 2034, driven by increasing demand for non-invasive diagnostics, rising chronic disease prevalence, and advances in genomics and liquid biopsy technologies. North America leads with 44% market share, while Asia-Pacific shows fastest growth. Key players include Roche, Abbott, Siemens Healthineers, and Thermo Fisher Scientific.
Read original at globenewswire-incSoFi Technologies relaunched its premium SoFi Plus membership in Q2 2026, reaching 206,000 paid subscribers with $24 million in annualized revenue. The subscription strategy is working, with 25% of subscribers adding additional products. Management aims for 1 million subscribers within a year, implying $120 million in annual revenue. Meanwhile, competitors Robinhood and Chime are expanding their financial services offerings.
Read original at zacks-investment-researchPRED, a peer-to-peer sports prediction exchange, has introduced trading fees averaging 1% for takers and 0% for makers, positioning itself as the lowest-cost option compared to competitors Kalshi (7%) and Polymarket (5%). The platform uses an identical fee calculation formula to competitors but with a lower coefficient of 2.5%, and has expanded football coverage to include La Liga, Champions League, Europa League, and MLS.
Read original at globenewswire-incLiquidia (LQDA) and Insmed (INSM) are compared as commercial-stage biopharmaceutical companies focused on pulmonary hypertension treatments. LQDA shows impressive commercial momentum with Yutrepia generating $170.4M in Q2 sales and achieving four consecutive profitable quarters, but faces heavy reliance on a single product. INSM offers a more diversified portfolio with Brinsupri's strong launch ($1.25-$1.40B 2026 guidance) and established Arikayce revenue, plus a broader pipeline. While LQDA has outperformed INSM significantly this year (106.9% vs -28.5%), analysts recommend INSM as the more compelling long-term choice due to its diversified revenue base and sustainable growth story.
Read original at zacks-investment-research